Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Horich William Todd 2. Date of Event Requiring Statement (Month/Day/Year) 03/01/2026 3. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN] (Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP, Commercial Operations 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) ROCKVILLE, MD 20850 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 4,832 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	02/14/2028	Common Stock	13,000	$39.4	D
Employee Stock Option (Right to Buy)	(2)	02/22/2029	Common Stock	14,000	$36.75	D
Employee Stock Option (Right to Buy)	(3)	02/19/2031	Common Stock	17,000	$29.61	D
Employee Stock Option (Right to Buy)	(4)	02/22/2032	Common Stock	18,000	$32.2	D
Employee Stock Option (Right to Buy)	(5)	02/23/2033	Common Stock	20,000	$38.6	D
Employee Stock Option (Right to Buy)	(6)	02/22/2034	Common Stock	25,000	$27.94	D
Employee Stock Option (Right to Buy)	(7)	02/19/2035	Common Stock	20,000	$33.52	D
Employee Stock Option (Right to Buy)	(8)	02/18/2036	Common Stock	13,500	$50.2	D
Restricted Stock Unit	(9)	(9)	Common Stock	6,250	(10)	D
Restricted Stock Unit	(11)	(11)	Common Stock	2,500	(10)	D
Restricted Stock Unit	(12)	(12)	Common Stock	3,375	(10)	D
Restricted Stock Unit	(13)	(13)	Common Stock	3,000	(10)	D
Performance Share Unit	(14)	(14)	Common Stock	3,750	$0	D
Performance Share Unit	(14)	(14)	Common Stock	1,125	$0	D
Performance Share Unit	(14)	(14)	Common Stock	2,625	$0	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Horich William Todd C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE ROCKVILLE, MD 20850			SVP, Commercial Operations

Signatures

/s/ Timothy C. Dec, as attorney-in-fact		03/10/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The option vests in four equal annual installments beginning on February 14, 2019.
(2)	The option vests in four equal annual installments beginning on February 22, 2020.
(3)	The option vests in four equal annual installments beginning on February 19, 2022.
(4)	The option vests in four equal annual installments beginning on February 22, 2023.
(5)	The option vests in four equal annual installments beginning on February 23, 2024.
(6)	The option vests in four equal annual installments beginning on February 22, 2025.
(7)	The option vests in four equal annual installments beginning on February 19, 2026.
(8)	The option vests in four equal annual installments beginning on February 18, 2027.
(9)	These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
(10)	Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
(11)	These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
(12)	These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
(13)	These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
(14)	On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
Remarks: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.